Akebia Therapeutics Q4 EPS $(0.05) Misses $(0.03) Estimate, Sales $57.620M Beat $48.373M Estimate.
Benzinga Newsdesk 8 months ago
EarningsEarnings BeatsEarnings MissesNews
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 85.19 percent. This is a 50 percent increase over losses of $(0.10) per share
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 85.19 percent. This is a 50 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $57.620 million which beat the analyst consensus estimate of $48.373 million by 19.12 percent. This is a 23.92 percent increase over sales of $46.497 million the same period last year.